Iron supplement in cancer patients receiving erythropoietin
- PMID: 15514387
- DOI: 10.1200/JCO.2004.04.860
Iron supplement in cancer patients receiving erythropoietin
Comment on
-
Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial.J Clin Oncol. 2004 Apr 1;22(7):1301-7. doi: 10.1200/JCO.2004.08.119. J Clin Oncol. 2004. PMID: 15051778 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
